<TABLE BORDER="0" BGCOLOR="#f6f6f6" WIDTH="100%">
   <TR>
      <TD>
         <b>Pros</b>
      </TD>
      <TD>
         <b>Cons</b>
      </TD>
   </TR>
   <TR>
      <TD valign="top">
          It may prevent or delay the recurrence of Leiomyosarcoma. Although most research has indicated that there is no difference in recurrence and survival rates between those who have and those who do not have adjuvant treatment, the numbers studied are small.<br>&nbsp;
      </TD>
      <TD valign="top">
          May make no difference in preventing or delaying the recurrence of Leiomyosarcoma. Most research has indicated that there is no difference in recurrence and survival rates between those who have and those who do not have adjuvant treatment, but the numbers studied are small.<br>&nbsp;
      </TD>
   </TR>
   <TR>
      <TD valign="top">
         May give the patient and the oncologist a greater peace of mind if he/she believes that adjuvant treatment will be helpful.<br>&nbsp;
      </TD>
      <TD valign="top">
         There is no direct way of evaluating the impact of adjuvant treatment, as there are no tumors to monitor. The only way to evaluate its effectiveness is with regard to recurrence.<br>&nbsp;
      </TD>
   </TR>
   <TR>
      <TD valign="top">
         Not having adjuvant treatment may increase the patient's sense of anxiety about the possibility of recurrence<br>&nbsp;
      </TD>
      <TD valign="top">
         The side effects of adjuvant treatment may be considerable, and are comparable to those of traditional therapies used for direct treatment. They take a toll on the body.<br>&nbsp;
      </TD>
   </TR>
   <TR>
      <TD valign="top">
         There might be some clinical trials set up to evaluate adjuvant treatment in certain situations.<br>&nbsp;
      </TD>
      <TD valign="top">
         The particular treatment used may have a life time limit for the human body and may be unavailable, or available only to a limited degree, should recurrence occur and the treatment be NECESSARY. For example, a drug, which has been frequently used for adjuvant chemotherapy, adriamycin, has such a life time limit. Radiation also has life time limits in each part of the body.<br>&nbsp;
      </TD>
   </TR>
   <TR>
      <TD valign="top"></TD>
      <TD valign="top">
         Some clinical trials may exclude persons who have had prior treatments.<br>&nbsp;
      </TD>
   </TR>
   <TR>
      <TD valign="top"></TD>
      <TD valign="top">
         Adjuvant treatment is expensive and might deplete financial resources needed for a future recurrence.<br>&nbsp;
      </TD>
   </TR>
</TABLE>